In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
Niagen Bioscience Inc (NASDAQ: NAGE) closed the day trading at $6.67 down -1.48% from the previous closing price of $6.77. In other words, the price has decreased by -$1.48 from its previous closing price. On the day, 0.9 million shares were traded. NAGE stock price reached its highest trading level at $6.72 during the session, while it also had its lowest trading level at $6.55.
Ratios:
For a better understanding of NAGE, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 8.28 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 25.24. For the most recent quarter (mrq), Quick Ratio is recorded 3.29 and its Current Ratio is at 4.12. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.03.
Upgrades & Downgrades
In the most recent recommendation for this company, Canaccord Genuity on May 27, 2025, initiated with a Buy rating and assigned the stock a target price of $13. B. Riley Securities Downgraded its Buy to Neutral on August 11, 2022, whereas the target price for the stock was revised from $6 to $2.40.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 14 ’25 when Pamir Ozan bought 4,465 shares for $6.81 per share. The transaction valued at 30,406 led to the insider holds 7,372 shares of the business.
Pamir Ozan bought 2,220 shares of NAGE for $15,210 on Nov 14 ’25. The Chief Financial Officer now owns 2,220 shares after completing the transaction at $6.85 per share. On Mar 07 ’25, another insider, Lopez Carlos Luis, who serves as the SVP, General Counsel of the company, bought 273 shares for $7.86 each. As a result, the insider paid 2,146 and bolstered with 2,251 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NAGE now has a Market Capitalization of 532306944 and an Enterprise Value of 473111552. As of this moment, Niagen’s Price-to-Earnings (P/E) ratio for their current fiscal year is 27.40, and their Forward P/E ratio for the next fiscal year is 22.67. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.47. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.27 while its Price-to-Book (P/B) ratio in mrq is 7.52. Its current Enterprise Value per Revenue stands at 3.794 whereas that against EBITDA is 23.563.
Stock Price History:
The Beta on a monthly basis for NAGE is 2.31, which has changed by -0.123521686 over the last 52 weeks, in comparison to a change of 0.12607694 over the same period for the S&P500. Over the past 52 weeks, NAGE has reached a high of $14.69, while it has fallen to a 52-week low of $5.16. The 50-Day Moving Average of the stock is -11.51%, while the 200-Day Moving Average is calculated to be -25.07%.
Shares Statistics:
Over the past 3-months, NAGE traded about 1.06M shares per day on average, while over the past 10 days, NAGE traded about 804150 shares per day. A total of 79.64M shares are outstanding, with a floating share count of 52.65M. Insiders hold about 34.03% of the company’s shares, while institutions hold 39.99% stake in the company. Shares short for NAGE as of 1763078400 were 5634298 with a Short Ratio of 5.33, compared to 1760486400 on 4172117. Therefore, it implies a Short% of Shares Outstanding of 5634298 and a Short% of Float of 10.6800005.
Earnings Estimates
The performance of Niagen Bioscience Inc (NAGE) in the stock market is under the watchful eye of 2.0 analysts actively contributing to its current rating.The consensus estimate for the next quarter is $0.05, with high estimates of $0.06 and low estimates of $0.05.
Analysts are recommending an EPS of between $0.19 and $0.17 for the fiscal current year, implying an average EPS of $0.18. EPS for the following year is $0.25, with 2.0 analysts recommending between $0.27 and $0.23.
Revenue Estimates
5 analysts predict $31.7M in revenue for. The current quarter. It ranges from a high estimate of $33M to a low estimate of $30.5M. As of. The current estimate, Niagen Bioscience Inc’s year-ago sales were $29.12MFor the next quarter, 5 analysts are estimating revenue of $35.44M. There is a high estimate of $36.2M for the next quarter, whereas the lowest estimate is $34M.
A total of 5 analysts have provided revenue estimates for NAGE’s current fiscal year. The highest revenue estimate was $128.6M, while the lowest revenue estimate was $126.08M, resulting in an average revenue estimate of $127.29M. In the same quarter a year ago, actual revenue was $99.6MBased on 4 analysts’ estimates, the company’s revenue will be $153.22M in the next fiscal year. The high estimate is $155M and the low estimate is $151.8M.
